Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
BioNTech SE
Bristol-Myers Squibb
Bristol-Myers Squibb
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Bristol-Myers Squibb
Daiichi Sankyo
AbbVie
BicycleTx Limited
Hoffmann-La Roche
Second Affiliated Hospital of Nanchang University
Eikon Therapeutics
Regeneron Pharmaceuticals
Shanghai Henlius Biotech
Universitätsklinikum Hamburg-Eppendorf
Institut Curie
Bio-Thera Solutions
Cancer Institute and Hospital, Chinese Academy of Medical Sciences